Pharmacophore-based models for therapeutic drugs against phosphorylated tau in Alzheimer's disease

Jangampalli Adi Pradeepkiran, Arubala Reddy, P (Hemachandra) Reddy

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Phosphorylated tau (P-tau) has received much attention in the field of Alzheimer's disease (AD), as a potential therapeutic target owing to its involvement with synaptic damage and neuronal dysfunction. The continuous failure of amyloid β (Aβ)-targeted therapeutics highlights the urgency to consider alternative therapeutic strategies for AD. The present review describes the latest developments in tau biology and function. It also explains abnormal interactions between P-tau with Aβ and the mitochondrial fission protein Drp1, leading to excessive mitochondrial fragmentation and synaptic damage in AD neurons. This article also addresses 3D pharmacophore-based drug models designed to treat patients with AD and other tauopathies.

Original languageEnglish (US)
JournalDrug Discovery Today
DOIs
StateAccepted/In press - Jan 1 2018
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Pharmacophore-based models for therapeutic drugs against phosphorylated tau in Alzheimer's disease'. Together they form a unique fingerprint.

  • Cite this